- COMMUNITY OUTREACH AND ENGAGEMENT (COE) The Ohio State University Comprehensive Cancer Center (OSUCCC) is a national and international leader in translational research, with a reputation for delivering high-quality patient care and effective outreach and education programs to residents of the state of Ohio - our catchment area (CA) - and beyond. The CA includes all 88 counties in Ohio, which have very diverse populations, with many underserved communities as well as urban, rural and Appalachian communities. Electra Paskett, PhD, MSPH (CC) Associate Director for Population Science and Community Outreach and Director of the Center for Cancer Health Equity (CCHE) leads the Community Outreach and Engagement (COE) efforts for the OSUCCC. The CCHE is at the core of our COE efforts supporting the OSUCCC mission to reduce cancer health disparities throughout the CA. The CCHE is co- led by Darrell Gray II, MD, MPH, FACG (CC), who oversees the COE initiatives with the Clinical Trials Office to improve the accrual of women and minorities to clinical trials. COE works in the CA to connect minority populations to screening, outreach and engagement services. They also work with basic, clinical and population science program leaders in the OSUCCC to cultivate interest in CA-focused research including working with the Government Relations team and key faculty across the Center to pursue policy initiatives that address the cancer burden. COE efforts are supported by two Community Advisory Boards (rural and urban) that inform the focus and scope of CCHE activities and provide ongoing feedback to the OSUCCC leadership and Program leaders. The high priority cancers for the OSUCCC include lung, breast, colorectal, prostate, endometrial, cervical cancer, thyroid, and leukemia, as well as tobacco use, obesity and HPV vaccination. OSUCCC research and/or outreach and engagement efforts are ongoing to address these priority areas, via partnerships between the COE, OSUCCC research program members, and the community. To assess the impact of COE and OSUCCC efforts we have developed a logic model that includes short-term metrics of COE success: expanded reach (community members, patients); impact (services provided, time to diagnosis); collaborations (community partners, researchers); initiatives (grants funded); and clinical trial accrual (especially of underrepresented populations); and long-term metrics success including: reduced prevalence of risk factors and cancer rates, and longevity and impact of community partnerships. Over the last five years, we have had significant impact on HPV vaccination rates, accrual of minorities to clinical trials, breast cancer detection rates, navigation to screening and treatment, implementing translation for non-English speaking patients, fostering research to address the cancer burden in the CA. COE future plans focus on the priority cancers/risk behaviors of the OSUCCC as well as on 1) ensuring adequate communication between the community and the OSUCCC researchers as it relates to addressing the cancer burden in the catchment area and 2) a focus across the lifespan and expand to populations we are just beginning to work with (Asian, pediatric, rural clinics, LGBTQ) in order to reduce the cancer burden in our CA.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10089998
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Malpeli, Giorgio; Barbi, Stefano; Greco, Corinna et al. (2018) MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma. Oncotarget 9:19961-19979
Talbert, Erin E; Lewis, Heather L; Farren, Matthew R et al. (2018) Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. J Cachexia Sarcopenia Muscle 9:358-368
Wang, Jin-Ting; Xie, Wen-Quan; Liu, Fa-Quan et al. (2018) NADH protect against radiation enteritis by enhancing autophagy and inhibiting inflammation through PI3K/AKT pathway. Am J Transl Res 10:1713-1721
Karpurapu, Manjula; Lee, Yong Gyu; Qian, Ziqing et al. (2018) Inhibition of nuclear factor of activated T cells (NFAT) c3 activation attenuates acute lung injury and pulmonary edema in murine models of sepsis. Oncotarget 9:10606-10620
Norquist, Barbara M; Brady, Mark F; Harrell, Maria I et al. (2018) Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 24:777-783
Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24:450-462
Tasselli, Giorgia; Filippucci, Sara; Borsella, Elisabetta et al. (2018) Yeast lipids from cardoon stalks, stranded driftwood and olive tree pruning residues as possible extra sources of oils for producing biofuels and biochemicals. Biotechnol Biofuels 11:147
Moliva, J I; Hossfeld, A P; Canan, C H et al. (2018) Exposure to human alveolar lining fluid enhances Mycobacterium bovis BCG vaccine efficacy against Mycobacterium tuberculosis infection in a CD8+ T-cell-dependent manner. Mucosal Immunol 11:968-978
Suarez-Kelly, Lorena P; Akagi, Keiko; Reeser, Julie W et al. (2018) Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosity. Cold Spring Harb Mol Case Stud 4:
Dalton, William S; Sullivan, Daniel; Ecsedy, Jeffrey et al. (2018) Patient Enrichment for Precision-Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials. Clin Pharmacol Ther 104:23-26

Showing the most recent 10 out of 2602 publications